ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2125

Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (VectraTM DA) Test and DAS28-ESR

J.W.J. Bijlsma1, M. Verhoef-Jurgens2, M.F. Bakker1, J.W.G. Jacobs1, F.P.J.G. Lafeber1, P.M.J. Welsing3, G. Cavet4, D. Chernoff4 and D.J. Haney4, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands, 4Crescendo Bioscience, Inc., South San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, methotrexate (MTX), prednisolone, prednisone and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The CAMERA II study (Computer Assisted Management in Early RA) demonstrated that the addition of prednisone to a MTX-based tight control strategy increased effectiveness of therapy, including reductions in disease activity, disability, and joint erosion, increased likelihood of achieving sustained remission, and less frequent need for biological treatment. The purpose of this study was to evaluate changes in biomarker levels over time with MTX and MTX + prednisone treatment.  

Methods:

Clinical and biomarker assessments were performed for 104 patients at multiple visits between Baseline (BL) and 1 year.  The average number of visits per patient was 4.  Clinical assessments were used to calculate the DAS28-ESR, and 12 serum biomarker concentrations were combined to produce a score between 1 and 100 using the MBDA algorithm, which is a validated biomarker-based measure of disease activity.  Association between DAS28-ESR response and Multi-Biomarker Disease Activity (MBDA) response was assessed using Spearman’s correlation.  Changes from BL were analyzed using the paired t-test. 

Results:

There was a significant association between change in DAS28-ESR from BL to 1 year and change in MBDA from BL to 1 year in both the MTX-only arm (r = 0.57, p < 0.001, n = 31) and in the MTX + prednisone arm (r = 0.57, p = 0.002, n = 28).  Improvements in DAS28-ESR (p < 0.001) and MBDA (p = 0.01) were observed as early as 1 month post-BL in the MTX + prednisone arm.  Significant reduction in disease activity in the MTX-only arm was first observed at 2 months for DAS28-ESR (p = 0.02) and at 4 months for MBDA (p = 0.03).

 

 

DAS28-ESR

 

MBDA

Timepoint

MTX

MTX + pred.

 

MTX

MTX + pred.

 

n

Mean Chg.

n

Mean Chg.

 

n

Mean Chg.

n

Mean Chg.

1 Month

16

-0.3   (p = 0.24)

11

-1.9 (p < 0.001)

 

18

-3   (p = 0.27)

14

-12   (p = 0.01)

2 Months

15

-0.7   (p = 0.02)

11

-2.4 (p < 0.001)

 

17

-3   (p = 0.25)

14

-11   (p = 0.02)

3 Months

22

-1.3 (p < 0.001)

13

-3.0 (p < 0.001)

 

25

-5   (p = 0.09)

17

-15 (p = 0.002)

4 Months

13

-1.8 (p < 0.001)

10

-3.9 (p < 0.001)

 

17

-9   (p = 0.03)

14

-19 (p = 0.003)

5 Months

15

-2.2 (p < 0.001)

10

-4.2 (p < 0.001)

 

18

-13 (p = 0.006)

12

-21 (p = 0.003)

6 Months

18

-2.8 (p < 0.001)

12

-3.0 (p = 0.001)

 

29

-20 (p < 0.001)

19

-16 (p < 0.001)

9 Months

17

-2.7 (p < 0.001)

12

-3.2 (p = 0.001)

 

24

-24 (p < 0.001)

17

-20 (p < 0.001)

12 Months

31

-2.8 (p < 0.001)

28

-3.1 (p < 0.001)

 

44

-20 (p < 0.001)

37

-16 (p < 0.001)

Conclusion:

The biomarker-based MBDA test and DAS28-ESR responded quickly to combination therapy with MTX and prednisone and were correlated with one another.  MBDA may be useful in combination with clinical assessment to evaluate early response to therapy with MTX or MTX + prednisone.


Disclosure:

J. W. J. Bijlsma,
None;

M. Verhoef-Jurgens,
None;

M. F. Bakker,
None;

J. W. G. Jacobs,
None;

F. P. J. G. Lafeber,
None;

P. M. J. Welsing,
None;

G. Cavet,

Crescendo Bioscience,

1,

Crescendo Bioscience,

3;

D. Chernoff,

Crescendo Bioscience, Inc.,

1,

Crescendo Bioscience, Inc.,

3;

D. J. Haney,

Crescendo Bioscience, Inc.,

1,

Crescendo Bioscience, Inc.,

3.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-to-methotrexate-plus-prednisone-in-camera-ii-using-a-multi-biomarker-disease-activity-vectratm-da-test-and-das28-esr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology